This post reports on an Issues Panel which was held at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. The title of the panel was: Developing cost effectiveness for decision making: what can be learnt from “Value Based Pricing”?
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions. Important research on a range of topics will be...
This research explores which approaches to pricing can produce the greatest efficiency and access to medicines within and across countries.
OHE collaborated on two articles published in the journal Health Economics recently.
OHE's contributions focused on approaches to implementing UK value-based assessment and the details of creating an EQ-5D-5L value set for England.
The Health Economists’ Study Group (HESG), based in the UK, was founded in 1972 to support and promote the work of health economists. Its members are from academic, commercial, and government settings.
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine.
Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the University of Washington, summarise the critical economic issues in the development of evidence of value for drugs and diagnostics that are part of personalised medicine.
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually works. Programmes typically include data collection and either implicitly or explicitly link pricing, reimbursement and/or revenue to what the data show.